Mycobacterial Diseases
Open Access
ISSN: 2161-1068
+44 20 3868 9735
ISSN: 2161-1068
+44 20 3868 9735
Shishoo CJ
India
Research Article
The Comparison of Conventional and Novel Fixed Dose Combination of Rifampicin and Isoniazid to Improve Bioavailability of Rifampicin for Treatment of Tuberculosis
Author(s): Sanjeev Sinha, Raghunandan P, Rashmita Pradhan, Shishoo CJ, Manish Nivsarkar, Padh H, Samantaray JC, Kamal Kishore and Pandey RMSanjeev Sinha, Raghunandan P, Rashmita Pradhan, Shishoo CJ, Manish Nivsarkar, Padh H, Samantaray JC, Kamal Kishore and Pandey RM
Background: Fixed-dose combinations (FDCs) of anti-tubercular drugs have been recommended as a step towards ensuring better treatment and compliance of patients receiving anti-tubercular therapy (ATT).
Methods: The study was an open-label and randomized controlled trial. Patients were randomized to receive daily treatment with the conventional FDC dosage formulation or the novel FDC formulation of rifampicin and isoniazid as a part of 4 drug ATT regimen. The outcome measures were sputum conversion rates, radiological response and clinical response.
Results: Of the 105 patients who were randomized 55 received the conventional FDC formulation while 50 received the novel FDC formulation. Of the 105 participants, 51 (48.6%) had PTB with the rest having extrapulmonary tuberculosis (EPTB). Of the 87 patients could be assesse.. Read More»
DOI:
10.4172/2161-1068.1000157
